Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aadi Bioscience (AADI)
NASDAQ:AADI
Aadi Bioscience (AADI) Stock Price & Analysis
445 Followers
AADI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $7.24
Previous Close$1.61
Volume41.12K
Average Volume (3M)221.16K
Market Cap
$39.16M
Enterprise Value-$47.58M
Total Cash (Recent Filing)$88.27M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 07, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding24,554,205
10 Day Avg. Volume208,193
30 Day Avg. Volume221,158
Standard Deviation0.21
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.39
Price to Sales (P/S)6.56
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.00
Enterprise Value/Gross Profit-2.21
Enterprise Value/Ebitda0.68
Forecast
1Y Price Target
$14.00Price Target Upside777.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aadi Bioscience News
Bulls Say, Bears Say
Bulls Say
Financial HealthAadi boasts a strong financial position with a robust $108.8M in cash, cash equivalents, and marketable securities.
Market OpportunityWith a substantial addressable market for TSC1/2 mutant tumors, Aadi is positioned to capitalize on a multi-billion dollar opportunity.
Product Sales GrowthAadi's Fyarro has shown impressive sales growth, quickly becoming the preferred treatment option in its market segment.
Bears Say
Drug Development RisksRisks include disappointing market uptake of FYARRO, and potential inability to develop the drug in other cancers.
EarningsFinancial results reported a net loss of $0.68 per share, which was in line with the estimated net loss of $0.62 per share.
SalesSales for FYARRO generated were $5.4M versus the prior estimate of $6.7M.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AADI FAQ
What was Aadi Bioscience’s price range in the past 12 months?
Aadi Bioscience lowest stock price was $1.28 and its highest was $7.24 in the past 12 months.
What is Aadi Bioscience’s market cap?
Currently, no data Available
When is Aadi Bioscience’s upcoming earnings report date?
Aadi Bioscience’s upcoming earnings report date is Aug 07, 2024 which is in 12 days.
How were Aadi Bioscience’s earnings last quarter?
Aadi Bioscience released its earnings results on May 08, 2024. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.624 by -$0.056.
Is Aadi Bioscience overvalued?
According to Wall Street analysts Aadi Bioscience’s price is currently Undervalued.
Does Aadi Bioscience pay dividends?
Aadi Bioscience does not currently pay dividends.
What is Aadi Bioscience’s EPS estimate?
Aadi Bioscience’s EPS estimate is -$0.69.
How many shares outstanding does Aadi Bioscience have?
Aadi Bioscience has 24,554,205 shares outstanding.
What happened to Aadi Bioscience’s price movement after its last earnings report?
Aadi Bioscience reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.624. Following the earnings report the stock price went down -12.796%.
Which hedge fund is a major shareholder of Aadi Bioscience?
Currently, no hedge funds are holding shares in AADI
---
Aadi Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (777.74% Upside)
$14.00 (777.74% Upside)
Blogger Sentiment
Neutral
AADI Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.80%
12-Months-Change
Fundamentals
Return on Equity
-58.22%
Trailing 12-Months
Asset Growth
-34.91%
Trailing 12-Months
Company Description
Aadi Bioscience
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
---
AADI Earnings Call
Q1 2024
0:00 / 0:00
---
AADI Stock 12 Month Forecast
Average Price Target
$14.00
▲(777.74% Upside)
Technical Analysis
Best Analysts Covering AADI
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-52.29%
assigned a buy rating 7 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.29% per trade.
---